Baidu
map

Cell Death Dis:紫杉醇可诱导淋巴管内皮细胞自噬促进癌症转移

2020-02-06 QQY MedSci原创

乳腺癌的细胞毒性疗法可以抑制原发肿瘤的生长,但会促进前哨淋巴结通过淋巴系统转移。但目前关于一线化疗对淋巴管内皮细胞的作用的研究还很少。在本研究中,研究人员发现紫杉醇,一种已批准用于治疗转移性或局部晚期乳腺癌的抗癌药物,可以诱导淋巴管内皮细胞(LEC)发生自噬来促进转移。虽然紫杉醇治疗在抑制LEC粘附方面的作用非常显著,但对细胞的存活并没有影响。紫杉醇通过诱导非Akt磷酸化自噬通路进而抑制LEC的迁

乳腺癌的细胞毒性疗法可以抑制原发肿瘤的生长,但会促进前哨淋巴结通过淋巴系统转移。但目前关于一线化疗对淋巴管内皮细胞的作用的研究还很少。

在本研究中,研究人员发现紫杉醇,一种已批准用于治疗转移性或局部晚期乳腺癌的抗癌药物,可以诱导淋巴管内皮细胞(LEC)发生自噬来促进转移。

虽然紫杉醇治疗在抑制LEC粘附方面的作用非常显著,但对细胞的存活并没有影响。紫杉醇通过诱导非Akt磷酸化自噬通路进而抑制LEC的迁移及分支点的形成。

在体内,紫杉醇能够介导淋巴管内皮细胞对肿瘤细胞表现出更高的通透性,而这种作用能够被自噬溶酶体抑制剂氯喹所逆转。

虽然紫杉醇可明显地减小肿瘤体积,但其会显著增加前哨淋巴结的转移。这种作用仅限于淋巴转移过程,类似于化学疗法不影响血液内皮细胞。

综上所述,该研究主要揭示了淋巴系统通过自噬的方式抵抗化疗,进而促进治疗恶性进展及转移病灶的形成。本研究为开发新的减少转移瘤数目的联合疗法提供了理论基础。

原始出处:

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2013163, encodeId=5a1220131639f, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Sep 01 20:30:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961852, encodeId=0c4619618526e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 20 16:30:00 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871561, encodeId=57f318e1561e1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Oct 01 23:30:00 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299346, encodeId=757e129934684, content=<a href='/topic/show?id=1dd5e8010f5' target=_blank style='color:#2F92EE;'>#细胞自噬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78010, encryptionId=1dd5e8010f5, topicName=细胞自噬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379111, encodeId=f90a13e91118c, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529379, encodeId=0f4915293e975, content=<a href='/topic/show?id=4735659e3cf' target=_blank style='color:#2F92EE;'>#淋巴管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65973, encryptionId=4735659e3cf, topicName=淋巴管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee7311933759, createdName=amyloid, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531521, encodeId=66c21531521a4, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378978, encodeId=55653e897835, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Fri Feb 07 07:09:27 CST 2020, time=2020-02-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2013163, encodeId=5a1220131639f, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Sep 01 20:30:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961852, encodeId=0c4619618526e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 20 16:30:00 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871561, encodeId=57f318e1561e1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Oct 01 23:30:00 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299346, encodeId=757e129934684, content=<a href='/topic/show?id=1dd5e8010f5' target=_blank style='color:#2F92EE;'>#细胞自噬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78010, encryptionId=1dd5e8010f5, topicName=细胞自噬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379111, encodeId=f90a13e91118c, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529379, encodeId=0f4915293e975, content=<a href='/topic/show?id=4735659e3cf' target=_blank style='color:#2F92EE;'>#淋巴管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65973, encryptionId=4735659e3cf, topicName=淋巴管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee7311933759, createdName=amyloid, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531521, encodeId=66c21531521a4, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378978, encodeId=55653e897835, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Fri Feb 07 07:09:27 CST 2020, time=2020-02-07, status=1, ipAttribution=)]
    2020-12-20 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=2013163, encodeId=5a1220131639f, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Sep 01 20:30:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961852, encodeId=0c4619618526e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 20 16:30:00 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871561, encodeId=57f318e1561e1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Oct 01 23:30:00 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299346, encodeId=757e129934684, content=<a href='/topic/show?id=1dd5e8010f5' target=_blank style='color:#2F92EE;'>#细胞自噬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78010, encryptionId=1dd5e8010f5, topicName=细胞自噬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379111, encodeId=f90a13e91118c, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529379, encodeId=0f4915293e975, content=<a href='/topic/show?id=4735659e3cf' target=_blank style='color:#2F92EE;'>#淋巴管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65973, encryptionId=4735659e3cf, topicName=淋巴管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee7311933759, createdName=amyloid, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531521, encodeId=66c21531521a4, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378978, encodeId=55653e897835, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Fri Feb 07 07:09:27 CST 2020, time=2020-02-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2013163, encodeId=5a1220131639f, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Sep 01 20:30:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961852, encodeId=0c4619618526e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 20 16:30:00 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871561, encodeId=57f318e1561e1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Oct 01 23:30:00 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299346, encodeId=757e129934684, content=<a href='/topic/show?id=1dd5e8010f5' target=_blank style='color:#2F92EE;'>#细胞自噬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78010, encryptionId=1dd5e8010f5, topicName=细胞自噬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379111, encodeId=f90a13e91118c, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529379, encodeId=0f4915293e975, content=<a href='/topic/show?id=4735659e3cf' target=_blank style='color:#2F92EE;'>#淋巴管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65973, encryptionId=4735659e3cf, topicName=淋巴管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee7311933759, createdName=amyloid, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531521, encodeId=66c21531521a4, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378978, encodeId=55653e897835, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Fri Feb 07 07:09:27 CST 2020, time=2020-02-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2013163, encodeId=5a1220131639f, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Sep 01 20:30:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961852, encodeId=0c4619618526e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 20 16:30:00 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871561, encodeId=57f318e1561e1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Oct 01 23:30:00 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299346, encodeId=757e129934684, content=<a href='/topic/show?id=1dd5e8010f5' target=_blank style='color:#2F92EE;'>#细胞自噬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78010, encryptionId=1dd5e8010f5, topicName=细胞自噬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379111, encodeId=f90a13e91118c, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529379, encodeId=0f4915293e975, content=<a href='/topic/show?id=4735659e3cf' target=_blank style='color:#2F92EE;'>#淋巴管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65973, encryptionId=4735659e3cf, topicName=淋巴管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee7311933759, createdName=amyloid, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531521, encodeId=66c21531521a4, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378978, encodeId=55653e897835, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Fri Feb 07 07:09:27 CST 2020, time=2020-02-07, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2013163, encodeId=5a1220131639f, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Sep 01 20:30:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961852, encodeId=0c4619618526e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 20 16:30:00 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871561, encodeId=57f318e1561e1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Oct 01 23:30:00 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299346, encodeId=757e129934684, content=<a href='/topic/show?id=1dd5e8010f5' target=_blank style='color:#2F92EE;'>#细胞自噬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78010, encryptionId=1dd5e8010f5, topicName=细胞自噬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379111, encodeId=f90a13e91118c, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529379, encodeId=0f4915293e975, content=<a href='/topic/show?id=4735659e3cf' target=_blank style='color:#2F92EE;'>#淋巴管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65973, encryptionId=4735659e3cf, topicName=淋巴管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee7311933759, createdName=amyloid, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531521, encodeId=66c21531521a4, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378978, encodeId=55653e897835, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Fri Feb 07 07:09:27 CST 2020, time=2020-02-07, status=1, ipAttribution=)]
    2020-02-08 amyloid
  7. [GetPortalCommentsPageByObjectIdResponse(id=2013163, encodeId=5a1220131639f, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Sep 01 20:30:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961852, encodeId=0c4619618526e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 20 16:30:00 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871561, encodeId=57f318e1561e1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Oct 01 23:30:00 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299346, encodeId=757e129934684, content=<a href='/topic/show?id=1dd5e8010f5' target=_blank style='color:#2F92EE;'>#细胞自噬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78010, encryptionId=1dd5e8010f5, topicName=细胞自噬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379111, encodeId=f90a13e91118c, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529379, encodeId=0f4915293e975, content=<a href='/topic/show?id=4735659e3cf' target=_blank style='color:#2F92EE;'>#淋巴管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65973, encryptionId=4735659e3cf, topicName=淋巴管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee7311933759, createdName=amyloid, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531521, encodeId=66c21531521a4, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378978, encodeId=55653e897835, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Fri Feb 07 07:09:27 CST 2020, time=2020-02-07, status=1, ipAttribution=)]
    2020-02-08 cy0328
  8. [GetPortalCommentsPageByObjectIdResponse(id=2013163, encodeId=5a1220131639f, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Sep 01 20:30:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961852, encodeId=0c4619618526e, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 20 16:30:00 CST 2020, time=2020-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871561, encodeId=57f318e1561e1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Oct 01 23:30:00 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299346, encodeId=757e129934684, content=<a href='/topic/show?id=1dd5e8010f5' target=_blank style='color:#2F92EE;'>#细胞自噬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78010, encryptionId=1dd5e8010f5, topicName=细胞自噬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379111, encodeId=f90a13e91118c, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529379, encodeId=0f4915293e975, content=<a href='/topic/show?id=4735659e3cf' target=_blank style='color:#2F92EE;'>#淋巴管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65973, encryptionId=4735659e3cf, topicName=淋巴管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee7311933759, createdName=amyloid, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531521, encodeId=66c21531521a4, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Feb 08 13:30:00 CST 2020, time=2020-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378978, encodeId=55653e897835, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Fri Feb 07 07:09:27 CST 2020, time=2020-02-07, status=1, ipAttribution=)]
    2020-02-07 thm112988

    0

相关资讯

2019 ESMO 瑞戈非尼120 mg联合紫杉醇二线治疗晚期食管胃癌,初显疗效

2019年欧洲肿瘤内科学会(ESMO)年会在西班牙巴塞罗那隆重举行。靶向联合治疗作为当前的肿瘤治疗趋势,有多项研究在会上发布。其中一项Ⅰb期的REPEAT研究(798P)探索了瑞戈非尼联合紫杉醇用于晚期食管胃癌二线或以上治疗,显示出良好的安全性和有前景的疗效。

Circulation:紫杉醇涂层球囊对患者死亡率的影响

近期一项涵盖关于股骨颈紫杉醇涂层球囊和支架介入的随机、对照试验(RCTs)的总结级的荟萃分析,确定了紫杉醇治疗的患者的过度晚期死亡率。研究人员评估了Stellarex药物涂层球囊(DCB)治疗股髂动脉疾病的安全性,并对所有参与Stellarex股髂动脉临床项目的患者数据进行了独立的荟萃分析。为了比较DCB或无涂层经皮血管腔内成形术(PTA)后的死亡率,研究人员收集了2个RCT的数据,其中包括419

Mol Cancer Ther:对抗三阴乳腺癌化疗耐药性,MPS1靶点新药“重振”紫杉醇功效

在乳腺癌里,有一种类叫做“三阴性乳腺癌”,尽管它大概只占乳腺癌总数的10%,但其造成的死亡病例,却占到了乳腺癌患者死亡数的1/4!由于该肿瘤细胞缺乏雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(Her2),其治疗一直缺乏有效的靶向药物来延缓其患者的无进展生存期。

欧盟批准罗氏的PD-L1单抗Tecentriq联合紫杉醇治疗三阴性乳腺癌

欧洲委员会批准将罗氏的PD-L1单抗Tecentriq(atezolizumab)与白蛋白结合型紫杉醇Abraxane(nab-paclitaxel)联合,用于治疗无法手术切除的局部晚期或转移性三阴性乳腺癌的成年患者。该组合的批准标志着欧洲第一个可用于三阴性乳腺癌的癌症免疫治疗方案,可用于肿瘤PD-L1表达率为1%及以上和未接受过化疗的转移性患者。

JAMA Oncol:紫杉醇、吉西他滨以及顺铂治疗转移性胰腺癌

紫杉醇、吉西他滨以及顺铂的三联疗法极大程度上提高了转移性胰腺癌患者生存期

Lancet:周剂量密集化疗对欧洲上皮性卵巢癌患者的疗效研究

周剂量密集化疗可以作为上皮性卵巢癌的一线治疗方法,但与欧洲主要人群的标准每3周化疗方案相比,周剂量密集化疗不能显著提高无进展生存率

Baidu
map
Baidu
map
Baidu
map